Abstract
A very rich collection of archival material is used to compare two anticancer drugs commercialised by multinationals collaborating with public sector research, one in the USA and one in France. The framework of national innovation systems is used to compare the innovative environments for each development (different institutional structures, research programmes, financing, industry–academic–government relationships, environmental concern, and intellectual property regimes). The empirical work was able to bring out the nuances and subtleties of each environment, the way in which innovation took place in practice, and some striking differences from what stereotypical accounts of innovation in each country would have suggested.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
